338 related articles for article (PubMed ID: 29185391)
21. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
22. New insight into cancer immunotherapy.
Escribese MM; Barber D
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of sarcomas.
Leventhal BG
Natl Cancer Inst Monogr; 1981 Apr; (56):183-7. PubMed ID: 6170891
[TBL] [Abstract][Full Text] [Related]
24. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
Sun L; Chen L; Li H
Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
[TBL] [Abstract][Full Text] [Related]
25. Sarcomas and the immune system: implications for therapeutic strategies.
Francescutti V; Skitzki JJ
Surg Oncol Clin N Am; 2012 Apr; 21(2):341-55. PubMed ID: 22365524
[TBL] [Abstract][Full Text] [Related]
26. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
27. Immunity against soft-tissue sarcomas.
Maki RG
Curr Oncol Rep; 2003 Jul; 5(4):282-7. PubMed ID: 12781069
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
29. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapeutic approaches to the treatment of bone and soft tissue sarcomas.
McClay EF; Slovin SF
Semin Oncol; 1989 Aug; 16(4):328-32. PubMed ID: 2474202
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Bone and Soft Tissue Sarcomas.
Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.
Yu Z; Ren P; Zhang X; Zhang T; Ma B
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1065-71. PubMed ID: 19671026
[TBL] [Abstract][Full Text] [Related]
33. Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy.
Townsend CM; Eilber FR; Morton DL
JAMA; 1976 Nov; 236(19):2187-9. PubMed ID: 989809
[TBL] [Abstract][Full Text] [Related]
34. Cryoimmunology for malignant bone and soft-tissue tumors.
Nishida H; Yamamoto N; Tanzawa Y; Tsuchiya H
Int J Clin Oncol; 2011 Apr; 16(2):109-17. PubMed ID: 21400111
[TBL] [Abstract][Full Text] [Related]
35. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
36. From vision to reality: deploying the immune system for treatment of sarcoma.
Wilky BA; Goldberg JM
Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5.
Tsukahara T; Kawaguchi S; Torigoe T; Asanuma H; Nakazawa E; Shimozawa K; Nabeta Y; Kimura S; Kaya M; Nagoya S; Wada T; Yamashita T; Sato N
Cancer Sci; 2006 Dec; 97(12):1374-80. PubMed ID: 16995877
[TBL] [Abstract][Full Text] [Related]
38. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Lucca LE; Hafler DA
Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
[TBL] [Abstract][Full Text] [Related]
39. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
Overwijk WW
Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
[TBL] [Abstract][Full Text] [Related]
40. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
MartÃn-Broto J; Moura DS; Van Tine BA
Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
